GlobeStar Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GSTC research report →
Price Chart
About the company
GlobeStar Therapeutics Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing proprietary drug formulations. These innovative treatments specifically target multiple sclerosis (MS) and various other neurodegenerative disorders. Established in 2016, the company was formerly known as AngioSoma, Inc.
- CEO
- James C. Katzaroff
- IPO
- 2011
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on GSTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $124.11K
- P/E
- -0.04
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- 72.89
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 148.30%
- ROIC
- 174.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,864,000
- Net Income
- $-1,949,000-31.0%
- EPS
- $-0.00+0.0%
- OCF Growth
- +37.1%
- FCF Growth
- +37.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.11
- RSI (14)
- 40
- Avg Volume
- 82
No earnings-call transcripts are available for GSTC yet.
- Free Float
- 93.0%
- Shares Outstanding
- 1.24B
- Float Shares
- 1.15B
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 23, 22 | Chicoski Robert | other | 0 |
| Feb 10, 21 | Chicoski Robert | other | 0 |
| Apr 3, 23 | KATZAROFF JAMES C | other | 7,042,253 |
| Apr 3, 23 | KATZAROFF JAMES C | other | 70,422,535 |
| Feb 24, 23 | KATZAROFF JAMES C | other | 35,000,000 |
| May 12, 21 | KATZAROFF JAMES C | other | 30,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GSTC coverage
Recent articles, reports, and earnings notes.
No research on GSTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GSTC report →Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials
accesswire.com · Mar 28
GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment
accesswire.com · Nov 2
Globestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis Treatment
accesswire.com · Sep 28
GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets
accesswire.com · Oct 11
GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.
accesswire.com · Oct 4
GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis
accesswire.com · Sep 20
GlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding Campaign
accesswire.com · Jul 21
GlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All Season
accesswire.com · Jul 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.